Best practices for the management of local-regional recurrent chordoma: a position paper by the chordoma global consensus group

Archive ouverte

Gronchi, A. | Fossati, P. | Akiyama, T. | Alapetite, C. | Baumann, M. | Blay, Jean-Yves | Bolle, S. | Boriani, S. | Bruzzi, P. | Capanna, R. | Caraceni, A. | Casadei, R. | Colia, V. | Debus, J. | Delaney, T. | Desai, A. | Dileo, P. | Dijkstra, S. | Doglietto, F. | Flanagan, A. | Froelich, S. | Gardner, P A. | Gelderblom, Hans | Gokaslan, Z L. | Haas, R. | Heery, C. | Hindi, N. | Hohenberger, P. | Hornicek, F. | Imai, R. | Jeys, L. | Jones, R L. | Kasper, Bernd | Kawai, A. | Krengli, M. | Leithner, A. | Logowska, I. | Martin Broto, J. | Mazzatenta, D. | Morosi, C. | Nicolai, P. | Norum, O J. | Patel, S. | Penel, Nicolas | Picci, P. | Pilotti, S. | Radaelli, S. | Ricchini, F. | Rutkowski, P. | Scheipl, S. | Sen, C. | Tamborini, E. | Thornton, K A. | Timmermann, B. | Torri, V. | Tunn, P U. | Uhl, M. | Yamada, Y. | Weber, D C. | Vanel, D. | Varga, P P. | Vleggeert-Lankamp, C La | Casali, Paolo | Sommer, J.

Edité par CCSD ; Elsevier -

International audience. Chordomas are rare, malignant bone tumors of the skull-base and axial skeleton. Until recently, there was no consensus among experts regarding appropriate clinical management of chordoma, resulting in inconsistent care and suboptimal outcomes for many patients. To address this shortcoming, the European Society of Medical Oncology (ESMO) and the Chordoma Foundation, the global chordoma patient advocacy group, convened a multi-disciplinary group of chordoma specialists to define by consensus evidence-based best practices for the optimal approach to chordoma. In January 2015, the first recommendations of this group were published, covering the management of primary and metastatic chordomas. Additional evidence and further discussion were needed to develop recommendations about the management of local-regional failures. Thus, ESMO and CF convened a second consensus group meeting in November 2015 to address the treatment of locally relapsed chordoma. This meeting involved over 60 specialists from Europe, the United States and Japan with expertise in treatment of patients with chordoma. The consensus achieved during that meeting is the subject of the present publication and complements the recommendations of the first position paper.

Suggestions

Du même auteur

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Archive ouverte | Bellera, C. | CCSD

International audience

An update on the management of sporadic desmoid-type fibromatosis: a european consensus initiative between sarcoma patients euronet (spaen) and european organization for research and treatment of cancer (eortc)/soft tissue and bone sarcoma group (stbsg)

Archive ouverte | Kasper, Bernd | CCSD

International audience. Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no e...

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS)

Archive ouverte | Casali, P. G. | CCSD

International audience. BackgroundIn 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk gastrointestinal stromal t...

Chargement des enrichissements...